Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

 
• By Joseph Haas, Ian Haydock, Anju Ghangurde, and Vibha Ravi

Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.

DealWatch_1200x675

More from Deals

More from Business